For: | Navadurong H, Prasoppokakorn T, Siriwong N, Phathong C, Teeyapun N, Tanasanvimon S, Thanapirom K, Komolmit P, Tangkijvanich P, Treeprasertsuk S, Chaiteerakij R. Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy. World J Gastrointest Oncol 2023; 15(10): 1771-1783 [PMID: 37969413 DOI: 10.4251/wjgo.v15.i10.1771] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v15/i10/1771.htm |
Number | Citing Articles |
1 |
Supachaya Sriphoosanaphan, Witthawat Pantumongkol, Wantanee Kulpeng, Chanchai Charonpongsuntorn, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Abhasnee Sobhonslidsuk, Pisit Tangkijvanich, Jincheng Wang. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand. PLOS ONE 2024; 19(3): e0300327 doi: 10.1371/journal.pone.0300327
|